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Introduction
Neuropathic pain affects 7–10% of the general population1 and 
has a major impact on physical health, psychological health 
and quality of life2. The response to analgesic treatment is often 
inadequate with only 40–60% of patients achieving partial relief, 
often at the cost of adverse effects3. The prevalence of neuropathic 
pain will increase due to the increasing prevalence of predisposing 
conditions, such as diabetes mellitus, and ageing, which is asso-
ciated with neuropathic pain1. There is an urgent clinical need to 
translate an increased preclinical level of understanding of neuro-
pathic into clinical practice. In particular we need to understand 
the pathophysiology of neuropathic pain in clinical cohorts.
Neuropathic pain arises as a consequence of a disease or lesion 
in the somatosensory nervous system4. However, not all patients 
with such a lesion develop neuropathic pain. We do not under-
stand why only a sub-group of patients with the same disease or 
neurological lesion develop neuropathic pain. The severity and 
impact of neuropathic pain vary between individuals with similar 
conditions5 and are unpredictable. A plausible explanation for 
the variation in neuropathic pain prevalence and severity is a 
complex interaction between genetic, psychosocial, and clinical 
risk factors in a vulnerable individual6–8.
A recent and significant advance in neuropathic pain research 
has been the development of clinical tools, such as standard-
ised questionnaires and quantitative sensory testing for sensory 
phenotyping, that differentiate and stratify neuropathic pain9–13. 
We have entered an era whereby patients can be phenotyped in 
unprecedented detail in terms of sensory profile, psychologi-
cal factors and physiological measures such as nerve excitability 
testing. We have the opportunity to combine major advances in 
phenotyping with genomics to improve our understanding of 
neuropathic pain.
Aims and objectives
DOLORisk is a multi-centre observational study that aims to 
understand the risk factors and determinants for neuropathic 
pain.
Primary objectives
The primary objectives of DOLORisk are (1) to identify the influ-
ence of demographic, psychological and clinical factors on the 
risk of developing and maintenance of neuropathic pain, and (2) to 
study the association of genetic factors with the risk of developing 
and maintaining neuropathic pain.
Secondary objectives
DOLORisk also aims to determine if patient stratification 
using physiological and psychological factors can predict 
neuropathic pain risk and progression. Based on the analysis of 
these risk factors, the study will lead to the development of a risk 




The first step was to develop a protocol that would be used 
by all participating centres to identify and characterise people 
with neuropathic pain. The instruments chosen to phenotype 
DOLORisk participants were the object of a consensus meet-
ing between the recruitment centres in October 2015. This was 
based on a recent international consensus on phenotyping neu-
ropathic pain (NeuroPPIC), led by the Special Interest Group on 
Neuropathic Pain (NeuPSIG), of the International Association 
for the Study of Pain14. The respective merits and reported accu-
racy of available scales, questionnaires and self-reported meas-
ures were discussed and the following were included in the final 
DOLORisk protocol (Table 1). The DOLORisk protocol has 
been aligned across all recruitment centres to make data integra-
tion possible. The “core” protocol consists of questionnaires only. 
All participants recruited complete the core protocol and are 
classified according to the presence and extent of any neuro-
pathic pain. This information will be used to look for genetic 
and basic clinical risk factors using the methods outlined below. 
The “extended” protocol consists of more detailed phenotyping 
and uses multiple tools. The tools used for any subject depend on 
the recruitment centre to which he or she is recruited (Table 2). 





Demographic information captured includes age, gender, 
weight, height, years in education, and working status.
Characterisation of pain 
The presence and duration of pain (and also dysaesthesia) 
are assessed. Family history of chronic pain is recorded. Pain 
medication (individual drugs, e.g. paracetamol or gabapentin, and 
dosage), analgesic relief obtained and adherence to medication 
are recorded according to the Brief Pain Inventory (BPI)15.
Pain intensity 
Intensity of the pain is assessed with two questionnaires: the 
Chronic Pain Grade (CPG)16 over the past three months, and 
the BPI’s subscale for assessment of average pain severity over 
24 hours (which uses an 11 point numerical rating scale). One 
additional item asks about average pain over the past seven days.
Pain quality
Neuropathic descriptors of the pain are characterised with 
three tools: the DN4 (Douleur Neuropathique en 4 questions)9, 
the Neuropathic Pain Symptom Inventory (NPSI)17, and the 
painDETECT10. The Michigan Neuropathy Screening Instrument 
(MNSI)18 is used specifically for diabetic neuropathy.
      Amendments from Version 1
We have added written protocols for conditioned pain modulation 
and undertaking skin biopsy samples as supplementary 
information. We have also provided clarification in some of 
the terminology used (for instance more precision in the term 
environment) and the rationale for: performing EEG, threshold 
tracking studies and including a list of body sites to map pain 
location. We have clarified the exclusion criteria in the longitudinal 
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Table 1. Questionnaires of the DOLORisk protocol.
Category Questionnaire Core Extended Reference
Demographics Age, gender, years in education, 
working status, weight, height X X
Characterisation of 
pain Presence and duration of pain X X
Family history Family history of chronic pain X
Pain medication Currently taking pain medication X X
Brief Pain Inventory – Usefulness of 
medication X
Cleeland and Ryan15
Adherence to medication X
Pain severity Chronic Pain Grade X X Von Korff, et al.16
Brief Pain Inventory – Pain Severity X Cleeland and Ryan15
Pain quality DN4 Questionnaire X X Bouhassira, et al.9
DN4 Examination X
Neuropathic Pain Symptom Inventory X Bouhassira, et al.17
PainDETECT X Freynhagen, et al.10
Pain location List of locations X X
Body map X
Pain interference PROMIS Pain Interference X Cella, et al.19
Pain catastrophizing Pain Catastrophizing Scale X X Sullivan, et al.20
Health status and 
quality of life 
EQ-5D-5L X X Herdman, et al.21
PROMIS Depression 4a 8a Cella, et al.19
PROMIS Anxiety 4a 8a





Michigan Neuropathy Screening 
Instrument X
Feldman, et al.18
Personality Ten Item Personality Inventory X X Gosling, et al.22
International Personality Item Pool 
(Emotional Stability) X
Goldberg23
Lifestyle Smoking X X Campbell, et al.24
Alcohol X X




The participants are asked to indicate in which body site they 
feel pain. This is assessed in two ways: a list of body sites and 
a body map. The participants are asked to identify all the body 
locations in which they experienced pain over the previous three 
months, and to mark the pain that bothers them the most. The 
body sites include: Back pain; Neck or shoulder pain; Facial or 
dental pain; Headache; Stomach ache or abdominal pain; Pain 
in the arms; Pain in the hands; Chest pain; Pain in the hips; 
Pain in the legs or knees; Pain in the feet; Pain throughout the 
body (widespread pain); Other pain. Using a list of body sites 
affected by pain provides alignment with pre-existing popula-
tion cohorts, and is compatible with the recommendations of van 
Hecke, et al.1. This will allow us to test the viability and feasibility 
of this approach to phenotyping neuropathic pain. Detailed 
body maps will be available for all participants in the extended 
protocol, which will provide additional accuracy and also 
enable direct comparison with the list of body sites.
The core and the extended protocols take a different approach to 
identify the location in which the participant should be asked to 
rate pain. The rationale for this is that the recommendation for 
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Table 2. Summary of tests performed during the DOLORisk protocol.
Cohort Protocol Neurological 
examination
TCSS TNSn Skin 
biopsy




Diabetes Extended X X X X X X X X
Traumatic nerve 
injury Extended X X X X
Surgery Extended X X X X
Chemotherapy Extended X X X X X
Extreme 
phenotypes Extended X X X X X
TCSS- Toronto clinical scoring system; TNSn- Total Neuropathy Score – Nurse; QST- Quantitative sensory testing;  
EEG - Electroencephalography; CPM- Conditioned pain modulation.
grading neuropathic pain is based upon pain and clinical signs 
in a neuroanatomically plausible distribution26. The core proto-
col is designed for the assessment of neuropathic pain of diverse 
aetiologies at population level, and there is no prior expectation 
as to the neuroanatomically plausible distribution. Then, par-
ticipants are asked to specify body regions in which they experi-
ence pain, and choose one body region in which the pain bothers 
them most. In the core protocol, participants are asked to answer 
the questions that relates to pain intensity, quality and interfer-
ence in respect to the body region in which pain bothers them 
most. The approach in the extended protocol is different because 
in these cohorts the likely aetiology of neuropathic pain is known 
and therefore the neuroanatomically plausible distribution is pre-
determined. For instance in diabetic neuropathy or chemotherapy 
induced neuropathy the neuroanatomically plausible distribution 
is the feet, whereas following post-traumatic nerve injury the neu-
roanatomically plausible distribution is the innervation territory 
of the affected nerve. Participants are explicitly asked by the inves-
tigator to focus on the neuroanatomically plausible distribution 
when answering the questions on pain intensity, quality and inter-
ference. To capture information on other types of pain we then 
ask about pain in other body regions.
Pain interference, quality of life and psychological variables
The Patient-Reported Outcomes Measurement Information 
System (PROMIS)19 questionnaires are used to assess various 
psychological and psychosocial variables. They include depres-
sion, anxiety, sleep disturbance, fatigue and pain interference. 
Two bespoke questions adapted from the existing population data 
ask about traumatic life experiences. The EQ-5D-5L21 measures 
quality of life with a visual analogue scale and five items 
evaluating the impact of pain on the ability of the participant to 
perform everyday tasks.
Two questionnaires assessing personality and in particular 
neuroticism are included in the DOLORisk protocol. The Ten-
Item Personality Inventory (TIPI)22 evaluates extraversion, 
agreeableness, conscientiousness, neuroticism, and openness to 
experience. The 10-item International Personality Item Pool’s 
(IPIP)23 representation of the Goldberg27 markers for Emotional 
Stability offers a more precise characterisation of neuroticism. 
Pain catastrophizing behaviours are recorded through the Pain 
Catastrophizing Scale (PCS)20. 
Lifestyle 
Smoking and alcohol are recorded according to Campbell, 
et al.24 The short form of the International Physical Activity 
Questionnaire (IPAQ)25 is included in the lifestyle variables to 
account for physical activity.
Clinical assessment and specialised investigations
Neurological examination 
A comprehensive structured upper and lower limb neurological 
examination is performed to detect clinical signs of a neurologi-
cal lesion such as a peripheral neuropathy5,28–30. The examination 
includes assessment of temperature (using Somedic RollTemp, 
Somedic AB, Sweden), light touch (using 10g monofilament) 
and pinprick sensation (using ‘Neurotip’), joint position sense 
(proprioception), vibration perception using a 128Hz tuning 
fork, deep-tendon reflexes (using a Queen square tendon hammer 
and recorded as present as normal, present with reinforcement, 
absent or brisk), muscle bulk, and motor power. The clinical 
findings for a length-dependent neuropathy are quantified with 
the Toronto Clinical Scoring System (TCSS)31. The Total Neu-
ropathy Score – Nurse (TNSn)32 is used for chemotherapy-induced 
neuropathy. For other causes of neuropathic pain the spatial 
extent of sensory deficits and sensory hypersensitivity is 
recorded on a body map.
Nerve conduction studies 
Nerve conduction tests, to confirm the presence of a length 
dependent neuropathy, are performed in line with those recom-
mended by the American Academy of Neurology and American 
Association of Electrodiagnostic Medicine33,34. Sural sensory and 
peroneal motor nerve conduction studies are performed in one 
lower extremity. If both studies are normal33 no further tests are 
performed. If either test is abnormal additional nerve conduction 
studies are performed that include: ipsilateral tibial motor nerve; 
contralateral sural sensory nerve, peroneal motor or tibial motor 
nerves; or ulnar sensory, median sensory, and ulnar motor nerves 
in one upper extremity. The minimum case definition criterion for 
electrodiagnostic confirmation of a length dependant neuropathy 
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is an abnormality of any attribute of nerve conduction studies in 
two separate nerves, one of which is the sural nerve. Variables 
such as skin temperature, age, height, gender, and weight are 
measured and accounted for when interpreting nerve conduc-
tion tests. Nerve conduction tests are not repeated if study 
participants have previous results available which were performed 
within the last 2 years. 
Electroencephalography 
Electroencephalography (EEG) reflects the summated activity of 
synchronised arrays of brain neurons. Recent studies found cor-
relations between several EEG parameters and pain perception 
in healthy subjects, suggesting that EEG can identify parameters 
that relate to the individual’s way of processing pain. Examining 
EEG parameters in peripheral neuropathy patients can poten-
tially identify those individual patterns of pain processing 
which are part of the array of factors that determine the final 
clinical pain phenotype35,36. Establishing EEG as an appro-
priate biomarker for pain perception relies on its accuracy to 
correctly classify subjects as belonging to the pain or no-pain 
conditions. In order to achieve this goal we follow the stand-
ard statistical steps of multivariate pattern analysis. A range 
of classifiers that distinguish the painful from the non-painful 
brain include measures of peak activity within the various 
EEG frequency bands per electrode, point to point connectivity 
between each of 64 electrodes, as well as identification of brain 
networks. This is expected to allow new understanding about 
the neurophysiological aspects of pain processing in the painful 
brain. The classification method finally employed will be the 
one with the highest classification accuracy on a test set after 
being trained on a separate training set.
Threshold tracking 
Threshold tracking is an electrophysiological tool that assesses 
nerve excitability37. Nerve excitability measures are deter-
mined by the biophysical properties of myelinated axons and the 
axon membrane potential. The information obtained about nerve 
properties is complementary to conventional nerve conduction 
studies: measurements of action potential amplitude and latency 
are limited indices of function, providing information only on 
the number of conducting fibres and the conduction velocity 
of the fastest, while threshold tracking is sensitive to membrane 
potential at the site of stimulation37. In DOLORisk several meas-
ures of axonal excitability, such as refractoriness, supernormality, 
strength-duration time constant and threshold electrotonus, are 
assessed. The excitability measures are recorded from the motor 
and sensory divisions of the median nerve in line with published 
recommendations38. This can also be used to model ion chan-
nel function. We will explore the relationship of these measures 
to the risk of developing neuropathic pain and the relationship to 
pain intensity. Training will be provided to clinicians perform-
ing threshold tracking measurements to ensure the reliability 
of the data and harmonisation of nerve excitability protocols 
in all centres.
Skin biopsy for intra-epidermal nerve fibre assessment 
Intra-epidermal nerve fibre density (IENFD) is a validated tool 
for the assessment of small fibre pathology39. In DOLORisk 
IENFD is determined from skin biopsy samples taken in accord-
ance with published guidelines provided by the European 
Federation of Neurological Societies/Peripheral Nerve Society 
Guideline on the utilisation of skin biopsy samples in the diagno-
sis of peripheral neuropathies (see supplementary file: Skin biopsy 
for intraepidermal nerve fibre assessment)39. The skin biopsies 
are taken at the end of the clinical assessment once all relevant 
investigations are completed. Participants do not under undergo 
a skin biopsy if they are on warfarin or found to have other 
contraindications.
Quantitative sensory testing 
Static tests
Quantitative sensory testing (QST) is a measure of sensory per-
ception in response to a defined sensory stimulus. This test can 
show abnormalities in sensory function and be used to gener-
ate a sensory profile in respect to different sensory modalities 
assessing both gain and loss of function. For bilateral neuropathic 
pain disorders such as peripheral neuropathy QST is performed 
unilaterally on the dorsum of the most affected foot. For unilat-
eral neuropathic pain disorders QST is performed bilaterally 
in the affected area and the contralateral equivalent body region 
(which acts as a helpful comparator). QST is performed accord-
ing to a modification of the previously published protocol of 
the German Research Network on Neuropathic Pain (DFNS)40. 
These modifications were made in order to improve efficiency 
when performed in a restricted timescale. The wind up ratio 
(WUR) is not performed unless the patient is having conditioned 
pain modulation (CPM) tests in which case it will be help-
ful to have a measure of central sensitisation. WUR is per-
formed on the forearm instead of the dorsum of the hand in 
order to minimise the influence of peripheral sensory loss on 
detection of central processes. Thermal sensory limen is per-
formed in those patients with peripheral neuropathy but not in 
peripheral nerve injury (a situation where it is less informa-
tive). The assessment of mechanical pain sensitivity is shortened 
and two rounds of tests are performed instead of the five rounds 
included in the full DFNS protocol. All other tests are identi-
cal to the DFNS protocol and all study sites will be trained and 
certificated in the DFNS protocol to promote standardisation. 
QST data is entered into the data analysis system, Equista 
(version 1.2.2., CASQUAR GmbH), which was developed 
by the DFNS. Equista transforms the raw QST data into 
z-scores thus normalising for age, gender, and the body location 
of testing41,42. A z-score of zero is equal to the mean of the 
population. A score of greater or less than two standard 
deviations from the mean indicates gain of function or loss 
of function, respectively.
Dynamic tests
Conditioned pain modulation (CPM) provides insight into an 
individual’s endogenous analgesic mechanisms43,44. It can be 
assessed in a non-invasive manner and may be a key vulner-
ability factor for chronic pain and has also been shown to be 
predictive of treatment response. The protocol for CPM testing is 
in keeping with published recommendations (see supplementary 
file: Protocol for conditioned pain modulation)45,46.
Genetics 
DNA is extracted from a whole blood sample collected at 
recruitment. The analysis will follow three complementary 
approaches: genome-wide association studies (GWAS); whole 
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exome sequencing to identify rare, high-impact coding variants; 
and targeted sequencing of selected candidate genes.
Definition of neuropathy
The participants who undergo the extended protocol are assessed 
for neuropathy (when this is considered a relevant possibility 
by the investigator e.g. a patient with diabetes) and in all cases 
are also graded for neuropathic pain. To diagnose peripheral 
neuropathy, we use the criteria outlined by Tesfaye, et al.47 that 
classify neuropathy as possible, probable or confirmed:
Possible peripheral neuropathy is defined as the presence either 
of sensory symptoms, i.e. decreased sensation (e.g. “asleep, 
numbness”), positive neuropathic sensory symptoms (e.g. prick-
ling or stabbing, burning or aching pain) predominantly in the toes, 
feet, or legs; or of sensory signs, i.e. symmetric decrease of distal 
sensation or unequivocally decreased or absent ankle reflexes.
Probable peripheral neuropathy corresponds to any two or more 
of the following: sensory symptoms (as above), decreased distal 
sensation, or unequivocally decreased or absent ankle reflexes.
Confirmed peripheral neuropathy is defined as the presence 
of an abnormality of nerve conduction studies and a sensory 
symptoms OR signs of neuropathy. If nerve conduction stud-
ies are normal, a validated measure of small fibre neuropathy 
(abnormal thermal thresholds on QST or reduced intra-epidermal 
nerve fibre density) may be used47.
Definition of neuropathic pain
The Neuropathic Pain Special Interest Group (NeuPSIG) of the 
International Association for the Study of Pain (IASP)’s grading for 
neuropathic pain48 is used to grade neuropathic pain for all study 
participants recruited. Each study participant’s pain is assessed 
using these published criteria as below. Possible neuropathic 
pain must fulfil criteria 1 and 2. Probable neuropathic pain must 
fulfil criteria 1, 2 and 3. Definite neuropathic pain must fulfil all 
4 criteria.
1.    Pain with a distinct neuroanatomically plausible distribu-
tion, e.g. pain symmetrically distributed in the extremities 
– completion of body map and clinical history.
2.    A history suggestive of a relevant lesion or disease 
affecting the peripheral or central somatosensory sys-
tem – e.g. diagnosis of diabetes mellitus and a history of 
neuropathy symptoms including decreased sensation, 
positive sensory symptoms, e.g. burning, aching pain 
mainly in the toes, feet or legs.
3.    Demonstration of distinct neuroanatomically plausible 
distribution of neuropathic pain – e.g. presence of clini-
cal signs of peripheral neuropathy, i.e. decreased distal 
sensation or decreased/absent ankle reflexes.
4.    Demonstration of the relevant lesion or disease by at least 
one confirmatory test – e.g. abnormality on either the 
nerve conduction tests or IENFD.
In the large, population-based cohorts, the core protocol per-
mits the ‘entry level’ approximation to a classification of “pos-
sible neuropathic pain”, based on the NeuroPPIC phenotyping 
consensus14. This includes positive responses to the DN4 screen-
ing questionnaire, and relevant site and severity of pain as 
outlined above. Additional information on diagnosis of any pain 
conditions will be available.
Cohorts
DOLORisk is a multi-centre cross-sectional and longitudinal 
observational study. Multiple cohorts with neuropathic pain 
from different causes will be included. Each cohort has its own 
specific inclusion and exclusion criteria, and follows a specific 
recruitment flow (Figure 1; Table 3–Table 5).
Population cohort
Generation Scotland: the Scottish Family Health Study (GS:
SFHS)49 and Genetics of Diabetes Audit and Research 
Tayside (GoDARTS)50 are population-based genetic epidemiology 
studies. DNA, socio-demographic and clinical data are available 
for 24,000 GS:SFHS participants and 20,000 (9,000 with diabe-
tes) GoDARTS participants across Scotland. Participants will be 
contacted by post and invited to complete the DOLORisk core 
protocol. After 18 months, enrolled participants will be invited 
to complete the same questionnaire to assess development, pro-
gression or remission of any pain. For the population cohorts it 
is estimated that between 7% (GS:SFHS) and 25% (GoDARTS) 
of those with chronic pain will have neuropathic pain51. 
Therefore, 1,500 participants with neuropathic pain and 3,000 
controls are anticipated from GS:SFHS and 2,000 participants 
with neuropathic pain and 4,000 controls are anticipated from 
GoDARTS.
Cross-sectional cohorts assessed with the extended 
protocol
Patients with peripheral neuropathic pain, e.g. diabetic neuropa-
thy, chemotherapy-induced neuropathy, and traumatic nerve injury 
will be recruited by the University of Oxford, Imperial College 
London, Kiel University, Technion – Israel Institute of Technol-
ogy, Neuroscience Technologies, and Aarhus University, from 
both primary and secondary care. Patients with extreme pain phe-
notypes, such as insensitivity to pain, will also be recruited. The 
study participants will be assessed as per the DOLORisk extended 
protocol.
Longitudinal cohorts assessed with the extended protocol
Patients undergoing mastectomy, thoracotomy or receiving chem-
otherapy will be recruited by INSERM (French National Insti-
tute for Health and Medical Research) and Aarhus University. 
The surgical cohort of study participants will be recruited among 
patients scheduled for lung surgery or breast cancer surgery. 
The study participants receiving chemotherapy will be recruited 
from patients diagnosed with colorectal cancer. All study par-
ticipants in this cohort will undergo the extended protocol before 
surgery or receiving chemotherapy. Thereafter, at different times 
ranging from 4 to 12 months participants will be re-assessed, 
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Figure 1. DOLORisk Recruitment flow. DK = Denmark, FR = France.
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Table 3. Inclusion and exclusion criteria for invitation to the population cohort for the DOLORisk protocol.
Inclusion criteria Exclusion criteria
Population cohort •   Previous participation with GoDARTS or GS:SFHS. 
•   Existing consent to be re-contacted. 
•   Identified as being currently alive. 
•   Currently has a postal address on file. 
•   ≥ 18 years.
•   Unable to give consent. 
•   No current postal address available. 
•   Identified as having died.
Table 4. Inclusion and exclusion criteria for the cross-sectional cohorts for the DOLORisk protocol.
Inclusion criteria Exclusion criteria
Peripheral 
neuropathic pain 
•    ≥18 years with a diagnosis of peripheral neuropathy 
based on a prior clinical assessment combined with 
supportive clinical investigations such as abnormal nerve 
conduction studies, reduced intraepidermal nerve or 
abnormal findings on quantitative sensory testing.
•    Symptoms highly suggestive of neuropathy that in the 
judgement of the clinical researcher are suitable for the 
study even if they do not fulfil other inclusion criteria.
•   Patients who do not fulfil any of the exclusion criteria. 
•   Diabetes cohorts: Type 1 or Type 2 diabetes
•   Pregnant.
•    Incapacity to give consent or to complete 
the study questionnaires due to insufficient 
language command or mental deficiencies.
•    Concurrent severe psychological or 
psychiatric disorders.
•    Moderate to severe pain from other 
causes that may confound assessment 
or reporting of pain (e.g. spinal canal 
stenosis).
•    Central nervous lesions, which may 
complicate somatosensory testing.
•    Patients who are in the opinion of the 




•    ≥16 years with a set of symptoms that resemble those 
seen on Paroxysmal Extreme Pain Disorder, Familial 
Episodic Pain Syndrome or Erythromelalgia.
•    Existing diagnosis of Paroxysmal Extreme Pain Disorder or 
Familial Episodic Pain Syndrome or Erythromelalgia.
•   Reduced pain sensibility.
•    First degree relatives of patients who meet diagnostic 
criteria for Paroxysmal Extreme Pain Disorder, Familial 
Episodic Pain Syndrome, Erythromelalgia or inability to 
experience pain.
•   Patients who do not fulfil any of the exclusion criteria.
•   Pregnant.
•    Incapacity to give consent or to complete 
the study questionnaires due to insufficient 
language command or mental deficiencies.
•    Concurrent severe psychological or 
psychiatric disorders, especially severe 
claustrophobia.
•    Moderate to severe pain arising as a 
consequence of other disorders causing 
pain but that are not associated with those 
mentioned before as channelopathies.
•    Central nervous system diseased that may 
complicate the somatosensory testing.
•    Patients who are in the opinion of the 
investigator unsuitable for participation in 
the study.
•    Treatment or topical capsaicin cream/
ointment or Lidocaine patch within 30 days 
prior to Day 1 on the skin area that will be 
tested.
•    Presence of oedema or any skin condition 
at the ankle level that may interfere with the 
microneurography procedure.
using the extended protocol, to determine the development of 
neuropathic pain (Figure 1). We expect to include 50 patients 
scheduled to undergo chemotherapy and 590 patients scheduled 
for lung or breast surgery.
Data analysis
Sample size calculation
The sample size for the protocol is largely based on the primary 
outcome, which is the number of participants to explore the genetic 
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Table 5. Inclusion and exclusion criteria for the longitudinal cohorts for the DOLORisk protocol.
Inclusion criteria Exclusion criteria
Chemotherapy •   ≥18 years. 
•   Diagnosed with high-risk colorectal cancer.
•    Planned adjuvant treatment with oxaliplatin and 
flourouracil (5-FU) or capecitabine (Pro 5-FU).
•   Known metastatic cancer. 
•   Previous treatment with chemotherapy.
•   Significant mental illness.
•   Alcohol abuse.
•   Known diabetes.
•   Significant neuropathic diseases.
•   Spinal cord stenosis. 
•   Peripheral vascular diseases (Fontaine >2).
•    Chronic pain with a pain intensity on a 0-10 numeric 
rating scale >5.
•    Patients who do not speak, read or understand Danish.
Thoracotomy •   ≥ 18 years.
•    Scheduled for lung cancer resection performed 
via thoracoscopy and/or thoracotomy, including 
lobectomy, bilobectomy, pneumonectomy, 
resection of the tracheobronchial bifurcation, 
wedge resection, sleeve resection and 
combinations hereof.
•    Willingness and ability to comply with study 
procedures as judged by the site investigator/ 
manager.
•    Expected availability for follow-up throughout the 
study.
•    Mental incapacity or language barriers precluding 
adequate understanding of study procedures.
•    Current alcohol or substance abuse according to the  
site investigator’s medical judgement.
•    Unsuitability for participation in the study for any other 
reason, e.g. due to a significant serious underlying 
condition (e.g. other cancer or AIDS), as determined by 
the site investigator/manager.
     ADDITIONALLY in FR: 
•   Previous surgery on the same area.
•    Surgery targeting only the pleura or mediastinum.
•    Peripheral neurological pathology or central (brain 
damage, multiple sclerosis) susceptible to interfere with 
the evaluation of the post-operative pain.
•    History of significant mental illness: psychosis, severe 
depression having motivated a hospitalisation, suicide 
attempt.
•    Current major depressive episode at the time of the 
evaluation.
•    Abuse of drug or psychoactive substance during the last 
six months.
•    Patients participating in another protocol of biomedical 
research.
Mastectomy •   Women ≥ 18 years.
•    Scheduled for breast cancer resection performed 
via lumpectomy (partial or segmental mastectomy) 
or mastectomy with or without sentinel lymph node 
biopsy and axillary lymph node dissection, and 
any combinations hereof.
•   Affiliated to a social security scheme. 
•    Danish/French language (read, written and 
spoken).
•    Willingness and ability to comply with study 
procedures as judged by the site investigator.
•    Expected availability for follow-up throughout the 
study.
•    Cognitive or psychological disorders incompatible with 
the respect and/or the understanding of the protocol.
•    Current alcohol or substance abuse according to the site  
investigator’s medical judgement. 
•    Unsuitability for participation in the study for any other 
reason, e.g. due to a significant serious underlying 
condition (e.g. other cancer or AIDS), as determined by 
the site investigator.
•   Previous surgery on the same area. 
•    Peripheral neurological pathology or central (brain 
damage, multiple sclerosis) susceptible to interfere with 
the evaluation of the post-operative pain. 
•    History of significant mental illness: psychosis, severe 
depression having motivated a hospitalisation, suicide 
attempt. 
•    Current major depressive episode at the time of 
assessment. 
•    Abuse of drug or psychoactive substance during the last 
six months 
•    Participating in another protocol of biomedical research.
•   Other cancer or AIDS. 
•   Scheduled for bilateral mastectomy.
•    Presence of chronic pain before the breast cancer 
surgery.
•    Workplace accident, litigation or search for 
compensation.
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risk factors of neuropathic pain. The main comparison will be 
between those study participants diagnosed with neuropathic 
pain and those are diagnosed with no pain or pain of non- 
neuropathic nature. We will also be exploring physiological 
and psychosocial risk factors and these outcomes will require 
smaller sample sizes.
For example, based on the CaTS power calculator52, we will 
have 80% power in an additive model with p=10-8, prevalence 
of neuropathic pain in the general population of 8%, with a dis-
ease allele frequency of 0.30 (GS:SFHS) or 0.38 (GoDARTS), 
and therefore a genotype relative risk of 1.34. Based on the CaTS 
GWAS power calculator52, with 1,500 cases and 3,000 controls 
(as in the GS:SFHS cohort), we will have 82.7% power to iden-
tify SNP associations with a significance level of 5×10−8, assum-
ing an additive model, a minor disease allele frequency of 0.3, a 
genotypic relative risk of 1.35, and a prevalence of the diabetic 
neuropathic pain in the general population of 10%1. 
For the extended phenotyping of painful versus painless diabetic 
neuropathy (estimating 1000 subjects in each group) we will 
have 80% power to detect an allelic odds ratio of 1.7 at genome 
wide significance level (p<5×10-8). We will also be able to cross- 
validate between these cohorts. We have identified a further 
cohort of diabetic neuropathy individuals in Sweden who will be 
available for replication genotyping. In collaboration with the 
SUMMIT consortium, we would also like to combine data across 
diverse diabetic complications in order to enhance the power to 
detect genetic determinants of the microvascular complications of 
diabetes.
Further sample size calculations have been performed 
depending on the individual outcome measures being 
measured.
QST 
Sample size was determined according to the warm detec-
tion threshold data for patients with diabetes5. This calculation 
revealed a minimum sample size of 34 was required per group for 
a power of >0.8 (difference in means 2.0; standard deviation 4.3; 
a = 0.05).
CPM 
A cohort of 53 subjects gives an 80% power in between group 
differences of >0.25 standard deviations equivalent to 1.0 to 
1.6 range on the 0-10 pain numerical rating scale using a typical 
QST parameter such as conditional pain modulation.
Data management
The University of Dundee’s Health Informatics Centre (HIC) 
Services acts as a hub for data management. HIC Services 
develops bespoke software to support secure data collection, pro-
vides recruitment support for clinical studies and manages a data 
entry service. All services provided by HIC are delivered within 
a secure Safe Haven environment to ensure data are managed 
safely and in compliance with Data Protection legislation. All 
HIC processes are governed by approved Standard Operating 
Procedures. The questionnaire data is collected during the 
visit either on a paper clinical report form, or on a digital one, 
depending on the centres. The data is then entered by the inves-
tigator in the DOLORisk database through a bespoke interface. 
In order to limit input errors, the interface includes data checks 
and acceptable ranges, for instance for age, height and weight. 
Oxford have access to the whole dataset and perform checks on 
the quality and completeness of the entered data. Issues such as 
missing data are fed back to the respective centres so that they 
can be addressed.
GoDARTS and GS:SFHS datasets are already hosted on secure 
HIC servers. Participants’ identities will be shielded at all times 
from the research team, according to the secure SOPs.
External datasets generated by DOLORisk will be sent to HIC 
in anonymised format. When ready, these updated datasets will 
be transferred to the analytics platform held on a separate server 
and network from the HIC data management function within a 
remote-access Safe Haven for research projects. It has full 
analytical functionality including software (e.g. R and SAS) 
and is supported by powerful processing. Remote access to the 
Safe Haven analytics platform is available to approved project 
researchers, after they have signed appropriate agreements. No 
individual-level data can be removed from the Safe Haven, but 
summary outputs of analysis are released, after prompt screen-
ing by HIC to ensure that no potentially identifiable information 
is included to reduce the risk of accidental disclosure. Clinical 
phenotype data will be linked in anonymised format to genomic 
outputs.
Ethics and dissemination
Ethic approvals were obtained at the national level. Details can 
be found in Table 6. Participants are included in the protocol only 
after having given their written informed consent. Their deci-
sion whether to take part, or withdrawal during the course of 
the study, in no way alters their normal medical care. The signed 
informed consent is obtained by the clinician in charge of the 
patient or the healthy volunteer.
Where possible, datasets will be made publicly available once 
the study is completed. Gene variants associated with neuro-
pathic pain risk will be entered into the existing PainNetworks 
database53 that undergoes longstanding curation by the London 
Pain Consortium. Transcriptional profiling data will be entered 
into painnetworks.org and ArrayExpress. We will enrich this with 
anonymised normative data on sensory profiling and physiologi-
cal variables. It will be possible to download clinical screening 
tools from the DOLORisk website.
Findings will be communicated to the scientific community via 
peer-reviewed publications (open access), and presentations at 
conferences. DOLORisk has partnered with patient organisa-
tions supporting people with pain and neuropathy-related disor-
ders such as Pain Association Scotland, the InDependent Diabetes 
Trust, and Fibromyalgia Action UK. The results of the study 
will be sent to the organisations periodically.
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Table 6. DOLORisk cohorts approvals. NT: Neuroscience Technologies. INSERM : Institut National de la Santé Et de la Recherche 
Médicale. CS: cross-sectional. Pro: prospective. REC: Research Ethics Committee. ANSM: Agence nationale de sécurité du médicament 
et des produits de santé (national agency for medicines and health products safety). CPP : Comité de protection des personnes (ethical 
research committee). CCTIRS: Comité consultatif sur le traitement de l’information en matière de recherche dans le domaine de la santé 
(advisory committee on data processing in health research). CNIL: Commission nationale de l’informatique et des libertés (data protection 
authority).
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Current study status
Recruitment started in 2016 and is ongoing in all centres. As of 
December 2017, 1,915 participants in GoDARTS and 7,240 
participants in Generation Scotland have returned the ques-
tionnaires of the core protocol. 1,062 participants have been 
recruited throughout the rest of the centres according to the 
extended protocol. All recruitment and follow-up activities are 
expected to be completed by mid-2019.
Data availability
No data are associated with this article.
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4. Data management: it is not clear if there is a computer-based data collection system with direct
data entry from each site, which then undergoes QC, or whether the data are collected on
paper-pencil CRFs, then entered to a some electronic format (e.g. spreadsheets) and transmitted
(via email?) to the University of Dundee HIC Services. This is important for controlling the steps
where potential errors can occur, and it would be useful to provide more specific steps of data











5. Table 5: the exclusion criteria for thoracotomy and mastectomy cohorts are quite different in
terms of components not related directly to the surgery (e.g. cognitive disorders, substance use). Is
















6. Table 5: the sentence "Receiving another treatment than oxaliplatin and flourouracil (5-FU) or
capecitabine (Pro 5-FU)." might be better worded as "receiving treatment other than oxaliplatin...".
In addition, the adjuvant FOLFOX regimen often includes Leucovorin. For such "hard" criteria of
excluding anything besides 5-FU/Capecitabline and oxaliplatin, the investigators may want to add
leucovorin. Also - some centers add bevacizumab to adjuvant FOLFOX regimens - consider either
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